Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
Cancer immunotherapy: the ultimate ally in the tumor war

Can immunotherapy cure cancer? Fighting cancer with our own immune system. It sounds promising. At the end of the 1800s, the controversial Dr. Wil…


Engineered immune cells to fight cancer

Our own immune T-cells can be one of the best defense lines against cancer. Walloon biopharmaceutical company Celyad is using an innovative approa…


Living on the edge: the challenge of doing things differently in cell therapy

Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science fo…

POPULAR TAGS

Celyad obtains FDA approval to initiate the NKR-2 CAR-T cells THINK trial in the USA

Written by DS on in the category news with the tags , , .


  • IND (Investigational New Drug) approval triggers the initiation of the THINK trial in the U.S.

  • Rosewell Park (NY) and University of Pittsburgh Medical Center – UPMC (PA) approved and ready to enroll patients.

  • No toxic event in the other patients enrolled in the study so far.


Celyad announced that the U.S. FDA authorized the initiation of the THINK trial in the U.S. THINK evaluates NKR-2 CAR-T cells in seven indications, five solid cancers and two hematological malignancies.

“The FDA approval for the THINK trial is an important milestone allowing us to initiate the THINK clinical trial in the USA. We are now looking forward to enrolling the first patients in both solid and hematological arms of the study in the U.S.”, said Christian Homsy, CEO of Celyad.

“I would like to thank the team as well as our partners for the incredible work achieved so far to make the THINK trial progress at such a good pace. In the coming months, all our efforts will be dedicated to the recruitment and follow-up of new patients for each dose-level cohort, but also to the opening of new clinical sites across EU and the U.S.”, remarked Jean-Pierre Latere, Chief Operating Officer at Celyad.

More news on Celyad

Read more about: , , .

RELATED ARTICLES
Cancer immunotherapy: the ultimate ally in the tumor war

Can immunotherapy cure cancer? Fighting cancer with our own immune system. It sounds promising. At the end of the 1800s, the controversial Dr. Wil…


Engineered immune cells to fight cancer

Our own immune T-cells can be one of the best defense lines against cancer. Walloon biopharmaceutical company Celyad is using an innovative approa…


Living on the edge: the challenge of doing things differently in cell therapy

Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science fo…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven Janssen Itera Life Science Turnstone UGent Flanders.bio GSK V-Bio Ventures Biowin XpandInnovation

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.